Garry E. Menzel - 05 Jun 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: Director
Issuer ticker: STOK
Reported as of: 05 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jun 2024, 16:21:31 UTC
Prior SEC filing: 10 Jul 2023
Next SEC filing: 06 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Garry E. Menzel filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 07 Jun 2024.

Key facts

This page summarizes Garry E. Menzel's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jun 2024, 16:21.

Change

Previous filing in this sequence was filed on 10 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +7,639
Change %
Price: $0.000000
Shares after: 7,639
Date: 05 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,639
Exercise price: $16.41
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.